In addition to trials sponsored by the medical industry, TriHealth hospitals participate in clinical research supported by grants from government organizations and private foundations. Such research is diverse; at any given time, research teams are conducting studies in several specialty areas: cardiology, cardiothoracic and vascular surgery, dermatology, neonatology, neurosurgery, obstetrics and gynecology, oncology, orthopedics, urogynecology, and would healing.
More than 20 grant-supported trials currently are being conducted. A selection of these trials is listed below; for more information or to participate, please call the appropriate contact person.
Other Clinical Trials
Other
|
Growth Regulation in Fetuses with Cardiac Malformations
Pl: Andrea Hinton MD Contact Person: Ganga Devaiah MS, 513 862 2341 or Ganga_devaiah@trihealth.com; or Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com
Inclusion Criteria:
- Fetal diagnosis of Hypoplastic Left Heart Syndrome
- Clinically obtained amniocentesis
Exclusion Criteria:
- Genetic syndrome diagnosis (e.g. Turner Syndrome)
- Mother with a condition that potentially results in growth abnormalities (e.g. preeclampsia, diabetes, abnormal quad screen).
- Advanced maternal age >35 years
- Mothers less than 18 years of age
|
Randomized Multi-Center of Antenatal Treatment of Alloimmune Thrombocytopenia
PI: William Polzin MD Contact Person: Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com
Inclusion Criteria: Very High Risk Group
- Pregnant women are eligible for inclusion into the very high risk group if they:
- Are PLA-1 negative and have known platelet incompatibility with their fetus
- Have had a previous child who suffered an antenatal hemorrhage prior to 28 weeks gestation
- Are less than study 19 weeks gestation
Exclusion Criteria: Very High Risk Group
- Women are not eligible for inclusion into the very high risk group if they:
- Have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation
- Are greater than 19 weeks gestation
Inclusion Criteria: High Risk Group
- Pregnant women are eligible for inclusion into the high risk group if they:
- Are PLA-1 negative and have known platelet incompatibility with the fetus
- Have had a previous child who suffered an antenatal hemorrhage after 28 weeks gestation
- Are between 12-30 weeks of gestation
Exclusion Criteria: High Risk Group
- Women are not eligible for inclusion into the high risk group if they:
- Have had a previous child who suffered an antenatal hemorrhage prior 28 weeks gestation
- Are greater than 30 weeks gestation
Inclusion Criteria: Standard Risk Group
- Pregnant women are eligible for inclusion into the standard risk group if they:
- Are PLA_1 negative and have known platelet incompatibility with the fetus
- Have not had a previous child who suffered an antenatal hemorrhage
- Are between 20-30 weeks of gestation
;
Exclusion Criteria: Standard Risk Group
- Women are not eligible for inclusion into the standard risk group if they:
- Have had a previous child who suffered an antenatal hemorrhage
- Are greater than 30 weeks gestation
|
Novel Biomarkers in Amniotic Fluid to Predict Fetal Lung Maturity and Clinical Respiratory Outcomes
PI: Beena Kamath MD Contact Person: Peggy Walsh RN, 513 862 2707 or Peggy_Walsh@TriHealth.com Inclusion Criteria:
- 18 years of age or older
- Pregnant between 34 to < 39 weeks gestation
- Amniocenteses
|
A Phase III, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of LIBIGEL for the Treatment of Hypoactive Sexual Desire (HSDD) in Postmenopausal Women
PI: Rachel Pauls MD Contact Person: Vivian Ghodsi RN CCRC, 513 463 4308 or Vivian_Ghodsi@TriHealth.com
- Inclusion Criteria: Closed to enrollment. Follow-up only
- Exclusion Criteria: Closed to enrollment. Follow-up only
|
Closure of Pfannenstiel Skin Incisions after Cesarean Delivery: A comparison of Metallic Staples versus Absorbable Staples
PI: Catherine Feese MD Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com
- Inclusion Criteria: Closed to enrollment. Follow-up only
- Exclusion Criteria: Closed to enrollment. Follow-up only
|
Fetal Lung Maturation in Twin Gestations Based on Birth Order and Weight Discordance
PI: Donna Lambers MD Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com
- Inclusion Criteria: Closed to enrollment. Follow-up only
- Exclusion Criteria: Closed to enrollment. Follow-up only
|
Assessment of Pain and Embarrassment with Urodynamic Testing in Women: A Prospective Study
PI: Rachel Pauls MD Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com
- Inclusion Criteria: Closed to enrollment. Follow-up only
- Exclusion Criteria: Closed to enrollment. Follow-up only
|
Mechanisms of Correction of Fetal Growth Restriction
PI: Mounira Habli MD Contact Person: Michaela Eschenbacher, MPH, 513 862 2341 or Michaela_Eschenbacher@TriHealth.com
- Inclusion: All healthy pregnant females between 19-45 scheduled for a csection at >37 weeks between Monday and Friday
- Exclusion: All preterm scheduled csections, medically complicated patients, and patients who refuse participation
|